Home | Sitemap | Search | ContactA- A A+
    Public Member Support us  
Home > News > TEXT & SOFT Results

TEXT & SOFT Results 


New treatment option for young women with hormone‐sensitive breast cancer.

The Aromatase Inhibitor (AI) Question

This landmark study is the first to demonstrate that taking exemestane along with blocking ovarian function prevents cancer recurrence in young women with hormone‐sensitive breast cancer, a common type of breast cancer. These practice‐changing results provide a new treatment option for young women with hormone‐sensitive breast cancer, previously only recommended for postmenopausal women. This IBCSG study is the culmination of a successful, decade‐long worldwide collaboration spanning 27 countries and 6 continents.

Press Release
Please contact press@ibcsg.org for media inquiries.

ASCO 2014 Plenary Presentation
Dr. Olivia Pagani presented on behalf of IBCSG at the June 1 plenary session.

New England Journal of Medicine
We are pleased to publish our results in the July 10 print issue of The New England Journal of Medicine.

  • Click to access the paper. Full content is available by paid subscription.

ASCO 2014 Related Abstracts
We also presented the following related TEXT and SOFT abstracts:

Women who participated in the TEXT and SOFT clinical trials should contact their treating physician for additional information.




The next IBCSG Annual Meeting will take place in Vienna Austria on March 23 and 24, 2019.       

16th St. Gallen International Breast Cancer Conference Primary Therapy of Early Breast Cancer

New publications are available 

All News